Skip to Content
MilliporeSigma

1.16883

Millipore

Fractogel® EMD DEAE (M)

Synonym(s):

Fractogel® EMD DEAE (M)

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115711

Quality Level

ligand

diethylaminoethyl

description

weak anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

sterility

sterile (Caustic Stable)

product line

Fractogel®

form

resin

parameter

170 cm/hr flow rate
8 bar max. pressure

matrix active group

methacrylate

mean particle size

40-90 μm

capacity

100 mg binding capacity (BSA/mg of resin)

transition temp

flash point 35 °C (calculated)

density

1.430 g/cm3

bulk density

1000 kg/m3

application(s)

gene therapy
mAb
vaccine development

separation technique

weak anion exchange

storage temp.

2-30°C

Looking for similar products? Visit Product Comparison Guide

General description

Weak anion exchange Fractogel® resin featuring the tentacle technology, for purification of acidic and neutral proteins and peptides from multiple sources, pDNA purification, DNA, RNA, and endotoxin removal, large viruses purification, vaccine purification, blood fractionation, and more

Features and Benefits

Fractogel® EMD DEAE (M) enables:

  • Excellent binding to large viruses and plasmid DNA
  • Homogenous binding with high selectivity and purity
  • Lower elution volumes for the highest purity levels
  • Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution


Due to the titration behavior, the ion exchange capacity can be used from pH 2 to pH 9.5. The separation of proteins is based on reversible electrostatic interactions between the negatively charged regions of the proteins′ surface and the support. Proteins are retained efficiently on Fractogel® EMD DEAE when the pH of the buffer is about 1 unit above their isoelectric points (pl).

The strength of the binding depends on the following:
  • the buffer system
  • pH value of the buffer which determines the surface charge of the protein
  • the degree of the ionization of the functional groups of the exchanger
  • the concentration of the counter ions
  • the charge density on the support (protein binding capacity)

Packaging

  • 1.16883.0100: Fractogel® EMD DEAE (M) Resin 100ml
  • 1.16883.0010: Fractogel® EMD DEAE (M) Resin 10ml
  • 1.16883.0500: Fractogel® EMD DEAE (M) Resin 500ml
  • 1.16883.5000: Fractogel® EMD DEAE (M) Resin 5L

Plastic bottle

Analysis Note

Appearance: Milky turbid suspension,free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin

Legal Information

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Pictograms

Flame

Signal Word

Warning

Hazard Statements

Hazard Classifications

Flam. Liq. 3

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

95.0 °F

Flash Point(C)

35 °C


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

See case study examples of how to optimize chromatographic purification of plasmid DNA for Biopharmaceutical Applications.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

See All

Related Content

A templated process produces live vector vaccines. Challenges: yield loss, filtration, aggregation, scaling. Collaboration overcomes manufacturing hurdles.

Tailored viral vaccine manufacturing addresses virus-specific challenges through collaboration.

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

This page summarizes key considerations related to regulatory expectations for biomanufacturing including chemicals and polymeric materials. For chemicals, topics include nitrosamines and elemental impurities, and for polymeric materials such as filters and single-use assemblies, the focus is qualification and extractable and leachable testing.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service